Establishment of a Myeloid Cell Line, YM711, Characterized by Retinoid Resistance

References

• Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, Gu L J, Wang Z Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Degos L, Chomienne C, Daniel M T, Berger R, Dombret H, Fenaux P, Castaigne S. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 1990; 2: 1440–1441
   Web of Science ®Google Scholar
• Warrell R P, Jr, Frankel S R, Miller W H, Jr, Scheinberg D A, Itri L M, Hittelman W N, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon M S, Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-transretinoic acid). N Engl J Med 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F, Bordessoule D, Sadoun A, Tiberghien P, Fegueux N, Daniel M T, Chomienne C, Degos L. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176–2181
   PubMed Web of Science ®Google Scholar
• Kakizuka A, Miller W H, Jr., Umesono K, Warrel R P, Jr, Frankel S R, Murty V VVS, Dmitrovsky E, Evans R M. Chromosomal translocation (15,17) in human acute promyelocytic leukaemia fuses RARα with a novel putative transcription factor PML. Cell 1991; 66: 663–674
   PubMed Web of Science ®Google Scholar
• Kane J R, Head D R, Balazs L, Hulshof M G, Motroni T A, Raimondi S C, Carroll A J, Behm F G, Krance R A, Shurtleff S A, Downing J R. Molecular analysis of the PML/RARα chimeric gene in pediatric acute promyelocytic leukemia. Leukemia 1996; 10: 1296–1302
   PubMed Web of Science ®Google Scholar
• Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard J F, Boivin P, Daniel M T, Berger R, Castaigne S, Degos L. Retinoic acid therapy for promyeloeytic leukacmia. Lancet 1989; 1: 746–747
   PubMedGoogle Scholar
• Castaigne S, Chomienne C, Daniel M T, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Chen Z X, Xue Y Q, Zhang R., Tao R F, Xia X M, Li C, Wang W, Zu W Y, Yao X Z, Ling B J. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419
   PubMed Web of Science ®Google Scholar
• Warrell R P, Jr, de The H, Wang Z Y, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Kizaki M, Nakajima H, Mori S, Koike T, Morikawa M, Ohta Saito M. M., Koeffler H P, Ikeda Y. Novel retinoic acid. 9-cis retinoic acid, in combination with all-trans retinoic acid is an effective inducer of differentiation of retinoic acid-resistant HL-60 cells. Blood 1994; 83: 3289–3297
   PubMed Web of Science ®Google Scholar
• Robertson K A, Emami B, Collins S J. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992; 80: 1885–1889
   PubMed Web of Science ®Google Scholar
• LI Y P, Said Gallagher F. RE. Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-α. Blood 1993; 83: 3298–3302
   Web of Science ®Google Scholar
• Hamada H, Tsuruo T. Functional role for the 170- to 180- kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83: 7785–7789
   PubMed Web of Science ®Google Scholar
• Warrell R P, Jr. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 1993; 82: 1949–1953
   PubMed Web of Science ®Google Scholar
• Muindi J RF, Frankel S R, Huselton C, DeGrazia F, Garland W A, Young C W, Warrell R P, Jr. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytie leukemia. Cancer Res 1992; 52: 2138–2142
   PubMed Web of Science ®Google Scholar
• Delva L, Monique C, Balitrand N, Guidez F, Miclea J-M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, Chomienne C. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175–2181
   PubMed Web of Science ®Google Scholar
• Maeda Y, Horiuchi F, Miyatake J, Sono H, Tatsumi Y, Urase F, Irimajiri K, Horiuchi A. Inhibition of growth and induction of apoptosis by all-trains retinoic acid in lymphoid cell lines transfected with the PML/RARα fusion gene. Br J Haematol 1996; 93: 973–976
   PubMed Web of Science ®Google Scholar
• Sumimoto Y, Maeda Y, Naiki Y, Sono H, Miyatake J, Sakaguchi M, Matsuda M, Kanamaru A. Exogenous PML/RARα fusion gene responds to all-trans retinoic acid results in differentiation of the human. B cell line., 3, (In submission)
   Google Scholar
• Maeda Y, Horiuchi F, Sumimoto Y, Miyatake J-Matsuda I. M., Tatsumi Y, Irimajiri K, Horiuchi A. Possible role of PML/RARα fusion gene in Leukemogenesis. Br J Haematol 1997; 97: 245
   PubMed Web of Science ®Google Scholar
• Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler H P, Ikeda Y. Mechamisms of retinoid resistance in leukemic cells: possible role of cytochrome p450 and p-glyeoprotein. Blood 1996; 87: 725–733
   PubMed Web of Science ®Google Scholar
• Muindi J F, Young C W. Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome p-450 isoforms. Cancer Res 1993; 53: 1226–1229
   PubMed Web of Science ®Google Scholar
• Muindi J F, Scher H I, Rigas J R, Warrell R P, Jr, Young C W. Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans retinoic acid in patients with advanced cancer. Cancer Res 1994; 54: 2125–2128
   PubMed Web of Science ®Google Scholar
• Zhou D-C, Hallam S. J., Lee S. J., Klein R. S., Wiernik P. H., Tallman M. S., Gallagher R. E. Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells. Cancer Res 1998; 58: 5770–5776
   PubMed Web of Science ®Google Scholar
• Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K. Retinobenzoic acids. I. Structure-activity relationship of aromatic amides with retinoidal activity. J Med Chem 1988; 31: 2182–2192
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shibata Shinjo Y. K., Yanagi M, Tobita T, Ohnishi K, Miyawaki S, Shudo K, Ohono R. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, AM80. Ann Int Med 1996; 124: 893–896
   PubMed Web of Science ®Google Scholar
• Liau G, Ong D E, Chytil F. Interaction of the retinol/cellular retinol binding protein complex with isolated nuclei and nuclear component. J. Cell Biol 1981; 91: 63–68
   PubMed Web of Science ®Google Scholar
• Takase S, Ong D E, Chytil F. Transfer of retinoic acid form its complex with cellular retinoic acid-binding protein to the nucleus. Arch Biochem Biophys 1986; 247: 328–334
   PubMed Web of Science ®Google Scholar